Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-101 in β-thalassemia
NCT06024876Phase 1Completed
- Sponsor
- CorrectSequence Therapeutics
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Gene Silencing, Adenine Base Editors, Cytosine Base Editors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS-101 in beta thalassemia, sponsored by CorrectSequence Therapeutics. Primary endpoints: Frequency and severity of adverse events at 12 months, Time to neutrophil and platelet engraftment and 5 more. Started Aug 2023; status: completed.
02
Drugs
CS-101
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06024876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024876.